The objective of the study is to enable access to sibling or autologous umbilical cord blood (UCB) infusions for children with various brain disorders. The use of UCB in this fashion is based on safety and efficacy data from prior and ongoing clinical trials at Duke University Medical Center in over 700 patients with these diagnoses infused with autologous or sibling UCB over the past decade.
- Study Type: Expanded Access
The primary purpose of this protocol is to enable access to sibling or autologous umbilical cord blood for children with various brain disorders. Children with autism, apraxia, cerebral palsy, hydrocephalus, hypoxic brain injury, stroke, and other brain injuries will be eligible if they do not qualify for or are unable to participate in another active clinical trial at Duke. Children with qualifying partially or fully matched sibling or autologous cord blood units will be eligible. The family will be enrolled on the screening protocol, "A Research Database and Screening Protocol for Children with Brain Injuries Potentially Undergoing Cellular Therapy or Other Clinical Trials," Pro00063563. Information may be obtained under this protocol including but not limited to: diagnostic information, genetic testing, videos and pictures of the child, cord blood report, etc. The PI or her designee will review this information to determine if the child might be eligible for a cord blood infusion(s) on this expanded access protocol. If eligible, the child must come to Duke with a parent or legal guardian for clinical evaluations and infusion of the umbilical cord blood unit. Parents will be required to participate in remote follow-up phone calls and be willing to complete questionnaires for safety follow-up.
- Biological: Cord Blood Infusion
- IV infusion of umbilical cord infusion (sibling or autologous)
Participating in This Clinical Trial
1. Have a qualifying sibling or autologous cord blood unit 2. Be < 26 years of age at the time of consent. 3. Have given written informed consent according to FDA guidelines (or consent of parent/legal guardian as applicable). 4. Have baseline blood counts and basic chemistries within normal for age. 5. Have a normal absolute lymphocyte count (ALC) for age on baseline blood count and differential. Exclusion Criteria:
1. Documented HIV or Hepatitis or other disease transmittable through the blood. 2. A cord blood unit that fails to meet specifications 3. Refusal of consent 4. Uncontrolled seizure disorder 5. Uncontrolled infection 6. Diagnosed with a genetic or metabolic disorder related to the neurologic condition 7. History of an immune deficiency 8. History of treatment with chemo or immunosuppressive therapy 9. History of previous allogeneic cell therapy. If previously enrolled on another Duke cell therapy protocol the subject can still be considered for enrollment on this study 10. Need for mechanical ventilation or chronic O2 support 11. History of inability to protect the airway 12. Eligibility for an active clinical trial of cellular therapies at Duke
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: 26 Years
- Lead Sponsor
- Joanne Kurtzberg, MD
- Provider of Information About this Clinical Study
- Sponsor-Investigator: Joanne Kurtzberg, MD, Professor of Pediatrics – Duke University
- Overall Official(s)
- Joanne Kurtzberg, Principal Investigator, Duke University
- Jessica Sun, Principal Investigator, Duke University
- Overall Contact(s)
- Lettie Moore, 9196681102, email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.